Innovent Biologics, Inc.
IVBXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$17.09B
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $17.09 Billion |
|---|---|
| Enterprise Value | $4.10 Billion |
| Earnings per Share | $0.47 |
| Beta | 0.24 |
| Outstanding Shares | 1,726,008,719 |
Return
| Return on Equity | 11.32% |
|---|---|
| Return on Assets | 5.64% |
| Return on Invested Capital | 7.10% |
Valuation & Multiples
| P/E Ratio | 95.4 |
|---|---|
| PEG | 198.23 |
| Price to Sales | 0.66 |
| Price to Book Ratio | 0.83 |
| Enterprise Value to Revenue | 0.15 |
| Enterprise Value to EBIT | 1.79 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 1.07 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 25, 2026
EPS Estimate
$0.07
Consensus analyst estimateRevenue Estimate
$1.31 B
Consensus analyst estimateNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$0.17
Consensus analyst estimateRevenue Estimate
$1.60 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Innovent Biologics, Inc.
8,754 employees
CEO: De-Chao Yu
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidat...